Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
about
Radiotherapy for advanced-stage aggressive non-Hodgkin lymphomaPutative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agentsCD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasCurrent challenges and novel treatment strategies in double hit lymphomasNext-generation prognostic assessment for diffuse large B-cell lymphomaConstitutive NF- κ B Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell LymphomaTumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunityDeveloping strategies in the immunotherapy of leukemiasNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewCorrelation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma.Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.BET inhibitors in the treatment of hematologic malignancies: current insights and future prospectsRadiotherapy for Non-Hodgkin's lymphoma: still standard practice and not an outdated treatment optionApproach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryThe European Hematology Association Roadmap for European Hematology Research: a consensus documentDiffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.Lenalidomide for the treatment of B-cell lymphoma.Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World DataPhase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphomaLenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial.Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.Socioeconomic disparities in lymphomaRituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma.Diffuse large B-cell lymphoma in elderly: Experience from a tertiary care oncology center in South India.EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP.A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absentReal world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis.Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States.Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas.Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantationDiagnosis of primary pulmonary T- cell/histiocyte-rich large B cell lymphoma with tissue eosinophilia via clinicopathological observation and molecular assay.Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy.Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOPPharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?
P2860
Q24187708-B30A118E-CD30-40C3-8229-1BAD9CC5A19FQ24297639-11738EE4-2451-45FB-8E25-BF918B3B8816Q26749139-C77D3FDF-72D0-4479-9891-6B9835C533FEQ26770385-5AEB6E22-8E1F-442E-9602-BFFEFD4A89FCQ26796428-A10583AD-BD0B-4BEA-9591-EE8AD564751FQ26853170-35282E65-8B4F-4877-ADD3-C25D168E3E46Q26862220-FBF0A9E2-D323-4EE3-9B75-CAAA1FD8220CQ26996310-12FF777D-535C-48F4-BADF-5C5978E835FFQ27304386-6E1828C7-A260-44BE-88E1-DA41196B27C0Q27314809-BA20D37B-CF59-4E4A-8DCD-23000D13CB83Q27853399-56C70DEE-CD1F-4553-A82B-0FB629819925Q28066765-DD13B573-AA7E-4867-9C91-F52FA0DD54ECQ28079951-3CD01C42-F25C-4037-AAB4-0821EA93BA44Q28088365-C96448D3-A507-47FC-88D8-2C92B9FDC9EEQ28830861-A3D9CB9F-BB08-4D26-BB3A-4EFDFEF27ED8Q30235296-3C32E3BF-42E6-4456-AFF3-682CC98B1420Q30249007-AE999B51-EFA8-4F2A-9724-67868099601EQ30249335-7CB04428-466A-4FCB-B00C-0D9F87093DB7Q30433183-B8E0890F-8565-4AA4-85C4-E599A3D7F4ADQ31036587-0B07530F-1E2C-4A4A-92EE-7E6F33D37EA0Q33406444-4A27B227-858F-4EFD-B324-A1C45E5B5E29Q33408772-6C6D74A8-7140-4912-98DD-E1AA08B84223Q33418655-FDBD3449-45C2-4198-BEE7-C67878099D4DQ33564294-7D1B3C45-4ECE-4020-90E8-79C61CF05C43Q33622342-1FED2A58-8F31-49DC-A89C-F388066FEC73Q33673144-49A873E0-5812-4AEA-A22D-92E62285D355Q33718800-A5F2866E-B504-4EFC-AF96-B6E6F73BB331Q33800959-EBC4165F-0212-4279-A3E8-7DCA5AB662DEQ33875883-A6569D22-AA90-4B4E-B4E9-171779075D88Q33896966-409BD269-FCEE-4D32-869C-8594ED67ED4DQ33909338-9C51C731-4247-4CD2-AD90-1931AF9ADC91Q33945770-660A3ABF-01B1-4759-A20A-72491D162F99Q34105982-81BEA304-7EF4-4EA6-8F2A-69C7C913ABBAQ34138121-94DA2502-B3C9-4636-8021-73B0989B6105Q34283822-3FA0C254-ECA4-425D-BD06-392F57FEEC38Q34325329-71FB4E2E-7FCB-4FB8-934C-A72EFADC6298Q34392965-473291E5-A25D-440B-96BE-F7E40A85ADB9Q34463466-E26AA25E-9F05-4A14-A119-E6A0FF068CC9Q34528537-1523A948-5B77-49B3-A09C-C970E0E43B80Q34757945-37F4C7F7-55D3-49DF-8058-38C09624E6EC
P2860
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Long-term outcome of patients ...... des des Lymphomes de l'Adulte.
@ast
Long-term outcome of patients ...... des des Lymphomes de l'Adulte.
@en
Long-term outcome of patients ...... des des Lymphomes de l'Adulte.
@nl
type
label
Long-term outcome of patients ...... des des Lymphomes de l'Adulte.
@ast
Long-term outcome of patients ...... des des Lymphomes de l'Adulte.
@en
Long-term outcome of patients ...... des des Lymphomes de l'Adulte.
@nl
prefLabel
Long-term outcome of patients ...... des des Lymphomes de l'Adulte.
@ast
Long-term outcome of patients ...... des des Lymphomes de l'Adulte.
@en
Long-term outcome of patients ...... des des Lymphomes de l'Adulte.
@nl
P2093
P2860
P1433
P1476
Long-term outcome of patients ...... des des Lymphomes de l'Adulte.
@en
P2093
Bertrand Coiffier
Catherine Sebban
Catherine Thieblemont
Christophe Fermé
Dominique Bordessoule
Eric Van Den Neste
Gérald Marit
Gérard Lepeu
Hervé Tilly
Isabelle Plantier
P2860
P304
P356
10.1182/BLOOD-2010-03-276246
P407
P577
2010-06-14T00:00:00Z